The Intersection of Polypharmacy and HHS: A Growing Clinical Concern

Managing patients with Hyperosmolar Hyperglycemic State (HHS) presents one of the most complex challenges in diabetes care. When polypharmacy—the simultaneous use of multiple medications—enters the picture, the complexity multiplies. HHS represents a severe diabetic complication defined by extreme hyperglycemia (blood glucose frequently exceeding 600 mg/dL), profound dehydration, and markedly elevated serum osmolality, typically occurring without significant ketosis. This condition predominantly affects older adults with type 2 diabetes who carry a heavy burden of comorbidities such as hypertension, cardiovascular disease, chronic kidney disease, and often cognitive impairment or functional decline. These coexisting conditions necessitate a multitude of drugs, each with distinct side-effect profiles and interaction potential. As the number of prescribed medications rises, so does the risk for adverse drug reactions, non-adherence, therapeutic failure, and hospitalization. This article explores how diabetic lens monitoring—an emerging technology providing non-invasive, real-time insight into glycemic control—can help address polypharmacy risks in the HHS population and enable more precise, safer medication management.

Understanding HHS and the Polypharmacy Burden

What Is HHS?

Hyperosmolar Hyperglycemic State is a life-threatening metabolic emergency seen almost exclusively in patients with type 2 diabetes. It is characterized by profound hyperglycemia, severe dehydration, and a marked increase in serum osmolality often exceeding 320 mOsm/kg. Unlike diabetic ketoacidosis (DKA), HHS typically lacks significant ketone accumulation due to residual insulin secretion that suppresses lipolysis. The condition is frequently precipitated by infection, acute illness, medication non-adherence, or use of drugs that impair glucose tolerance—including corticosteroids, thiazide diuretics, and atypical antipsychotics. Management requires aggressive fluid resuscitation, electrolyte replacement, and insulin therapy, usually in an intensive care setting. Mortality rates remain substantial, ranging from 10% to 20% in older adults, making prevention and optimal long-term management critical.

Polypharmacy in the HHS Population

Polypharmacy is commonly defined as the use of five or more medications, though some definitions extend to ten or more. Among HHS patients, the prevalence is exceptionally high because of typical age (≥65 years) and multiple chronic conditions. A typical patient might be prescribed antihypertensives including ACE inhibitors or angiotensin receptor blockers, calcium channel blockers, thiazide diuretics, statins, antiplatelet agents such as aspirin or clopidogrel, metformin, sulfonylureas or SGLT2 inhibitors, insulin, and potentially additional drugs for chronic kidney disease, heart failure, gout, or osteoporosis. Each additional drug increases the probability of clinically significant interactions. For example, diuretics can worsen dehydration and electrolyte imbalances; beta-blockers can mask hypoglycemic symptoms; SGLT2 inhibitors, while beneficial for heart and kidney outcomes, carry a risk of euglycemic DKA that can be mistaken for HHS; and nonsteroidal anti-inflammatory drugs can impair renal function and blunt the response to diuretics. This pharmacological complexity makes it challenging to attribute adverse events such as falls, confusion, or renal impairment to a single cause, often leading to prescribing cascades where new drugs are added to treat side effects of existing ones.

The Risks of Polypharmacy in HHS Patients

In the context of HHS, polypharmacy poses several heightened risks beyond those seen in the general diabetic population:

  • Increased likelihood of drug–drug interactions: Many medications used in diabetes and its comorbidities affect kidney function, electrolyte balance, and the renin-angiotensin system. Combinations can lead to hyperkalemia, hyponatremia, or acute kidney injury, precipitating or worsening HHS. For instance, concurrent use of ACE inhibitors and potassium-sparing diuretics can cause life-threatening hyperkalemia, while SGLT2 inhibitors combined with loop diuretics may exacerbate volume depletion.
  • Adverse drug reactions that mimic HHS symptoms: Drugs such as atypical antipsychotics (e.g., olanzapine, quetiapine), corticosteroids, and thiazide diuretics can induce hyperglycemia. Other agents may cause altered mental status, making clinical assessment difficult. Anticholinergic medications, common in older adults for bladder control or Parkinson's disease, can worsen dehydration and constipation, indirectly contributing to HHS.
  • Medication non-adherence: Complex regimens with multiple daily doses and varied timing lead to unintentional omissions or duplications. In HHS, missing doses of insulin or oral hypoglycemics can trigger a life-threatening episode. Cognitive impairment, common in this population, further compounds adherence challenges.
  • Higher hospitalization rates and costs: Studies consistently show that polypharmacy increases the risk of emergency department visits and hospital admissions, many of which are drug-related. The financial burden is substantial, with drug-related hospitalizations costing the U.S. healthcare system billions annually. For Medicare beneficiaries with diabetes, the average number of prescriptions exceeds ten per patient.

The Promise of Diabetic Lens Monitoring

How Lens Monitoring Works

Diabetic lens monitoring encompasses two complementary technologies that use the eye as a window into systemic glucose control. The first approach involves a soft contact lens embedded with a miniaturized glucose sensor. This lens measures glucose levels in tears—a reliable proxy for blood glucose—and transmits data wirelessly to a reader or smartphone app. Continuous monitoring over 24 to 48 hours provides a dynamic picture of glycemic fluctuations without the need for repeated finger-stick blood tests. The second approach uses non-invasive retinal imaging techniques such as fundus photography or optical coherence tomography (OCT) to detect early signs of diabetic retinopathy, which serves as an indicator of long-term glycemic control and microvascular damage. Both methods offer the promise of timely, objective data that can guide medication adjustments with greater precision than traditional intermittent monitoring alone.

Evidence Supporting Lens Monitoring for Glycemic Control

Several clinical studies have demonstrated the feasibility and accuracy of contact lens glucose sensors. A 2019 study published in Nature Communications showed that a flexible, transparent graphene-based lens could continuously measure glucose in tears with a strong correlation to blood glucose levels across a clinically relevant range. Another trial published in Biosensors and Bioelectronics (2021) confirmed that prototype sensors could detect hyperglycemic episodes and provide alerts, with a response time of under five minutes. Additionally, large-scale screening programs using OCT have demonstrated that detecting early retinopathy allows clinicians to intervene earlier, reducing the need for aggressive polypharmacy later. The Diabetic Retinopathy Clinical Research Network has shown that early detection and treatment of retinopathy can slow progression and reduce vision loss, indirectly supporting better glycemic management. While the technology is still evolving, its potential to replace or complement traditional glucose monitoring is significant, especially for patients who are non-adherent to frequent finger-stick testing or who have limited dexterity or vision.

Synergistic Benefits: Reducing Polypharmacy Through Better Monitoring

Medication Optimization and Deprescribing

The real-time data from diabetic lens monitoring empowers clinicians to make more informed decisions about medication regimens. For instance, if continuous glucose trends reveal that a patient experiences nighttime hyperglycemia, the dose of basal insulin can be adjusted upward, potentially allowing reduction of a prandial insulin or oral agent. Conversely, if frequent hypoglycemia is detected—particularly overnight or between meals—sulfonylureas or rapid-acting insulin can be reduced. This targeted approach supports deprescribing, the planned reduction of unnecessary or harmful medications, which is a key principle of geriatric care. In HHS patients, minimizing polypharmacy has the potential to lower the risk of recurrent episodes and improve overall safety. Tools like the Beers Criteria and STOPP/START criteria can be applied alongside lens monitoring data to identify medications that may be inappropriate or no longer necessary.

Enhanced Adherence and Patient Engagement

Lens monitoring also addresses a major driver of polypharmacy failure: non-adherence. When patients can see their glucose levels changing in real time on a smartphone, they become more engaged in their own care. The visual feedback from the lens—for example, a color-coded alert when glucose enters a dangerous range—serves as a powerful motivator. This is especially valuable for HHS patients who may be cognitively impaired or have limited health literacy. By simplifying data capture and making it accessible, lens monitoring reduces the burden of self-management. As adherence improves, clinicians are less likely to add rescue medications or escalate doses unnecessarily, indirectly reducing polypharmacy. Studies have shown that continuous glucose monitoring improves time-in-range and reduces HbA1c, and similar benefits are anticipated with lens-based monitoring.

Identification of Drug-Induced Glycemic Variability

One of the most valuable contributions of lens monitoring is the ability to identify drug-induced glycemic variability that might otherwise go unnoticed. For example, a patient on corticosteroids for chronic obstructive pulmonary disease may show predictable hyperglycemic spikes after each dose, allowing clinicians to adjust insulin timing or consider steroid-sparing alternatives. Similarly, beta-blockers can blunt the autonomic warning signs of hypoglycemia, and lens monitoring can detect silent hypoglycemic episodes that might otherwise lead to severe events. By providing a continuous record of glucose trends, lens monitoring enables clinicians to correlate medication changes with glycemic outcomes, facilitating more rational prescribing and deprescribing decisions.

Implementing Lens Monitoring in Clinical Practice

Technology Selection and Cost Considerations

Currently, no FDA-approved continuous glucose monitoring contact lens is available for commercial use, but several prototypes are in regulatory review. Meanwhile, retinal imaging for diabetic retinopathy is widely reimbursed and accessible. Practices looking to adopt lens monitoring should evaluate both options: a short-term sensor lens for glycemic profiling (for example, during a hospital stay or clinic visit) and periodic OCT or fundus photography for long-term vascular assessment. Cost will vary; contact lens sensors may initially be expensive but could offset costs by reducing hospitalizations and medication waste. Clinics should consider pilot programs and engage with payers to demonstrate value through reduced adverse events and improved outcomes.

Training and Workflow Integration

Successful integration requires that physicians, diabetes educators, and nursing staff understand how to interpret the data from lens monitors. Training programs should cover insertion and removal of the sensor lens (if applicable), connection to mobile devices, and interpretation of trend graphs. For retinal imaging, existing workflows for diabetic eye exams can be adapted to include more frequent monitoring in high-risk HHS patients. Electronic health records should be configured to accept data feeds from these devices, ideally with clinical decision support tools that flag concerning trends. A multidisciplinary team—including endocrinology, pharmacy, ophthalmology, and primary care—can collaborate to review lens monitoring data and adjust medications weekly or as needed.

Patient Education and Empowerment

Patients must be educated about the purpose and technique of lens monitoring. For contact lens sensors, they need instruction on hygiene, wearing schedules, and what to do if the device causes discomfort. For retinal imaging, providers should explain that the procedure is painless and takes only minutes. Providers should emphasize that the goal is not just to track numbers but to use that information to improve medication safety and reduce pill burden. Empowering patients with their own data fosters a partnership model that has been shown to improve clinical outcomes. Educational materials should be available in plain language and appropriate for patients with limited health literacy.

Challenges and Limitations

Despite its promise, diabetic lens monitoring is not without hurdles. Accuracy of tear glucose measurement can be affected by eye conditions such as dry eye syndrome, allergies, or infection. Contact lens wear may not be tolerated by all patients, especially older adults with fragile corneas or those who have difficulty with insertion and removal. Cost and access remain significant barriers; many patients with HHS are uninsured or underinsured, and the devices may not yet be covered by Medicare or private insurance. Furthermore, integration into existing diabetes management algorithms requires validation through large-scale clinical trials. Retinal imaging, while more established, does not provide real-time trends; it captures a snapshot of chronic damage and cannot guide daily medication adjustments. Therefore, a combined approach using both sensor lenses and periodic retinal imaging may be necessary. Clinicians must also be aware of potential data overload and guard against over-diagnosis or overtreatment based on transient fluctuations that may not reflect true clinical need. Additionally, data security and patient privacy concerns must be addressed as these devices transmit health information wirelessly.

Future Directions

Research is ongoing into next-generation lenses that can monitor not only glucose but also markers of inflammation or ketones, which could directly help predict HHS events. Artificial intelligence algorithms are being developed to analyze lens monitoring data and suggest personalized medication adjustments automatically, reducing the cognitive burden on clinicians. Integration with closed-loop insulin delivery systems—so-called artificial pancreas technology—is a realistic near-term goal that could further reduce polypharmacy by automating insulin dosing based on real-time glucose data. Advances in materials science are making lenses more comfortable and durable, with extended wear times of up to two weeks. As these technologies mature, we anticipate that diabetic lens monitoring will become a standard part of the armamentarium against polypharmacy in HHS patients, enabling truly individualized, data-driven care that improves outcomes and reduces the burden of complex medication regimens.

Conclusion

Addressing polypharmacy in HHS patients is a pressing clinical challenge that demands innovative solutions. Diabetic lens monitoring offers a non-invasive, patient-engaging method to obtain continuous glycemic data and detect early ocular complications, supporting more rational medication management. While the field is still developing, early evidence and practical benefits make it a compelling addition to clinical practice. By reducing guesswork, improving adherence, and enabling deprescribing, lens monitoring can help clinicians navigate the dangerous waters of polypharmacy and improve outcomes for some of the most vulnerable patients. Healthcare systems should invest in training, technology, and protocols to accelerate adoption. As we move toward a future of precision medicine, lens monitoring represents a practical step toward safer, more effective diabetes care for patients living with HHS and the many medications that accompany it.

For further reading: